Haemonetics Corporation

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-04-19 pm EDT			5-day change	1st Jan Change
81.24 ^USD	-2.66%		-4.67%	-4.99%

Apr. 04	Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge	MT
Apr. 04	Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge	CI

Haemonetics Corporation's Equity Buyback announced on May 7, 2019, has expired with 1,482,554 shares, representing 2.92% for $175 million.

May 05, 2021

The company expired its plan on May 6, 2021.

Latest news about Haemonetics Corporation

Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge	Apr. 04	MT
Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge	Apr. 04	CI
Haemonetics Corporation completed the acquisition of Advanced Cooling Therapy, Inc.	Mar. 31	CI
Haemonetics to Acquire Attune Medical for $160 Million	Mar. 05	MT
Haemonetics Q3 Adjusted Earnings, Revenue Increase; Shares Rise	Feb. 08	MT
Transcript : Haemonetics Corporation, Q3 2024 Earnings Call, Feb 08, 2024	Feb. 08
North American Morning Briefing : S&P 500 to Open -2-	Feb. 08	DJ
Haemonetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2023	Feb. 08	CI
Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024	Feb. 08	CI
Transcript : Haemonetics Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	Jan. 09
Haemonetics Completes $255 Million Acquisition of OpSens	Dec. 12	MT
OpSens Brief: NYSE's Haemonetics Completed Acquisition	Dec. 12	MT
Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).	Dec. 11	CI
OpSens Receives Final Order For Its Acquisition By NYSE's Haemonetics	Dec. 08	MT
OpSens Brief: Says Received Final Order For Its Acquisition By NYSE's Haemonetics	Dec. 08	MT
Opsens Shareholders Approve Arrangement With Haemonetics	Dec. 01	MT
OpSens Brief: In connection with prior announced acquisition by Haemonetics Obtained Regulatory Clearance of Arrangement in the US and Canada; Regulatory Approvals Condition Satisfied	Nov. 28	MT
OpSens Fiscal Q4 Loss Narrows as Sales Rise 57% Ahead of Acquisition by Haemonetics	Nov. 22	MT
OpSens Brief: ISS Recommends Shareholders Vote For Opsens Inc. Plan of Arrangement with NYSE's Haemonetics	Nov. 13	MT
Barrington Cuts Price Target on Haemonetics to $105 From $114 on 'Macro Concerns', Keeps Outperform Rating	Nov. 03	MT
Transcript : Haemonetics Corporation, Q2 2024 Earnings Call, Nov 02, 2023	Nov. 02
Haemonetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 02	CI
Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024	Nov. 02	CI
Haemonetics Seeks M&A	Nov. 01	CI
Barrington Research's Initial Take on Haemonetics' Acquisition of OpSens	23-10-11	MT

Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-09 - Q4 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Haemonetics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

83.46 USD

Average target price

107.2 USD

Spread / Average Target

+28.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
HAEMONETICS CORPORATION	-4.99%	4.24B
ABBOTT LABORATORIES	-2.53%	183B
MEDTRONIC PLC	-3.52%	105B
DEXCOM, INC.	+5.33%	51.77B
CENCORA, INC.	+16.43%	47.29B
HOYA CORPORATION	-1.73%	40.2B
WEST PHARMACEUTICAL SERVICES, INC.	+5.66%	27.62B
METTLER-TOLEDO INTERNATIONAL, INC.	-2.01%	25.51B
TERUMO CORPORATION	+9.84%	24.73B
ZIMMER BIOMET HOLDINGS, INC.	-1.87%	24.52B

Other Medical Equipment, Supplies & Distribution